polici
devic
manag
us
regul
team
medic
devic
compani
nonprofit
organ
effort
creat
better
tool
evalu
safeti
efficaci
health
technolog
medic
devic
innov
consortium
mdic
publicpriv
partnership
launch
last
month
us
food
drug
administr
fda
collabor
lifesci
alley
minnesotabas
trade
associ
industri
time
manufactur
call
fda
speed
product
review
public
advocaci
group
argu
agenc
nt
enough
protect
consum
success
mdic
depend
robust
govern
fda
ensur
effect
represent
across
stakehold
group
public
health
need
say
dale
nordenberg
execut
director
medic
devic
innov
safeti
secur
consortium
independ
profession
organ
new
york
central
coi
govern
host
singl
harmon
databas
biomed
research
tie
pharmaceut
industri
list
conflict
interest
coi
accord
expert
panel
conven
us
institut
medicin
iom
central
system
iom
committe
note
novemb
report
could
access
everi
time
inform
requir
grant
applic
journal
submiss
therebi
increas
transpar
reduc
repetit
paperwork
uniformli
defin
data
save
journal
univers
profession
societi
govern
agenc
state
feder
level
work
cost
creat
maintain
coi
form
say
panel
member
ross
mckinney
pediatr
infecti
diseas
specialist
duke
univers
school
medicin
durham
north
carolina
workforc
overhaul
us
nation
institut
health
nih
unveil
plan
last
month
increas
post
doc
stipend
launch
program
prepar
scientist
nonacadem
career
spend
million
next
decad
encourag
minor
research
pursu
biomed
research
career
among
measur
initi
come
respons
june
report
work
group
nih
advisori
committe
director
found
problem
agenc
exist
train
system
treatment
africanamerican
scientist
busi
cometriq
cometh
year
exist
exelixi
final
first
market
drug
novemb
fda
approv
south
san
firm
cometriq
cabozantinib
smallmolecul
inhibitor
tyrosin
kinas
met
treatment
medullari
thyroid
cancer
rare
form
diseas
phase
trial
present
last
year
american
societi
clinic
oncolog
meet
chicago
particip
took
cometriq
live
averag
month
without
tumor
growth
compar
four
month
receiv
placebo
treatment
respons
dramat
say
univers
diego
razel
kurzrock
led
earli
clinic
trial
involv
cometriq
everybodi
type
respons
tumor
stabil
realli
prolong
period
time
mening
mileston
european
regul
recommend
approv
first
vaccin
bacterium
caus
type
b
mening
deadli
form
brain
inflammatori
condit
account
meningococc
diseas
case
eu
countri
previous
vaccin
target
four
main
subgroup
neisseria
meningitidi
develop
use
fragment
sugar
bacterium
outer
membran
howev
techniqu
nt
work
serogroup
b
human
immun
system
nt
recogn
strain
sugar
coat
foreign
new
vaccin
bexsero
receiv
posit
review
european
medicin
agenc
committe
midnovemb
scientist
decod
genet
makeup
bacterium
discov
multipl
protein
taken
togeth
provid
protect
type
b
mening
accord
alison
patti
spokesperson
us
center
diseas
control
prevent
atlanta
agenc
work
maker
bexsero
switzerland
novarti
test
product
us
amgen
scoop
busi
bankrupt
decod
genet
say
publish
perish
two
outcom
mutual
exclus
evidenc
fate
decod
genet
reykjavikbas
compani
announc
bankruptci
million
asset
million
debt
acquir
decemb
california
biotech
giant
amgen
amgen
paid
million
cash
decod
made
name
establish
huge
genet
databas
iceland
popul
demonstr
larg
number
natur
genet
public
year
decod
research
team
prolif
peak
year
poor
invest
decis
caus
share
price
plummet
ultim
purchas
synergist
amgen
discoveri
effort
use
decod
platform
evalu
current
pipelin
optim
right
target
pursu
rapid
develop
say
eric
schmidt
analyst
new
financi
servic
compani
cowen
co
peopl
texa
twostep
embattl
cancer
prevent
research
institut
texa
found
new
chief
scientif
offic
lost
execut
director
last
month
day
decemb
press
releas
austinbas
institut
announc
margaret
kripk
cancer
immunologist
former
chief
academ
offic
md
anderson
cancer
center
houston
would
succeed
nobel
laureat
alfr
gilman
resign
top
scientist
job
octob
protest
institut
handl
peerreview
process
day
execut
director
william
gimson
tender
resign
state
place
situat
could
longer
effect
hhmi
head
scientist
howard
hugh
medic
institut
hhmi
appoint
member
flagship
research
program
new
vice
presid
chief
scientif
offic
molecular
biologist
erin
oshea
pictur
hhmi
investig
sinc
director
faculti
art
scienc
center
system
biolog
harvard
univers
cambridg
massachusett
sinc
began
duti
marylandbas
medic
research
organ
parttim
month
transit
fulltim
work
juli
posit
offer
opportun
identifi
support
great
scientist
develop
test
program
serv
model
other
support
develop
dissemin
transform
technolog
oshea
told
natur
medicin
review
ringlead
toni
scarpa
announc
retir
head
nih
center
scientif
review
csr
agenc
brought
psychologist
longtim
nih
administr
richard
nakamura
serv
act
director
grant
review
hub
decemb
appoint
made
perman
nakamura
previous
spent
year
agenc
nation
institut
mental
health
serv
scientif
director
deputi
director
select
list
applic
two
intern
nih
candid
sign
david
kaplan
nih
plan
stick
statu
quo
insid
wo
nt
chang
anyth
substant
say
kaplan
immunologist
case
western
reserv
univers
cleveland
studi
peerreview
process
csr
realli
requir
rethink
whole
process
manag
exactli
someth
nih
want
research
prenat
showdown
genet
abnorm
develop
fetus
spot
accur
chromosom
microarray
karyotyp
test
accord
largest
headtohead
trial
two
diagnost
techniqu
studi
fetal
dna
expect
mother
high
risk
children
birth
defect
us
team
found
microarray
analysi
reveal
clinic
relev
delet
duplic
around
sampl
despit
fetal
dna
display
normal
karyotyp
n
engl
j
med
find
undoubtedli
caus
mani
clinic
laboratori
geneticist
consid
whether
chromosom
microarray
recommend
firsttier
prenat
diagnost
test
say
cynthia
morton
director
cytogenet
brigham
women
hospit
boston
involv
trial
see
newli
discov
form
cell
divis
may
help
ward
cancer
cell
biologist
long
thought
cytokinesi
final
step
cell
divis
cytoplasm
content
split
necessari
proper
assort
chromosom
disrupt
process
prevail
wisdom
held
aneuploidi
result
cancer
implic
team
led
mark
burkard
univers
discov
new
type
cell
divis
dub
klerokinesi
protect
cell
fail
cytokinesi
use
livecel
imag
research
watch
retin
pigment
epitheli
cell
five
day
chemic
inhibit
cytokinesi
report
decemb
american
societi
cell
biolog
annual
meet
san
francisco
show
mani
cell
manag
split
two
first
growth
phase
next
cell
recov
normal
chromosom
set
burkard
say
therapeut
strategi
boost
type
nonmitot
cell
fission
could
prevent
cancer
peopl
high
risk
develop
tumor
mark
abnorm
chromosom
count
onlin
new
compound
thwart
parkinson
protein
gonaturecomzhcji
mysteri
new
coronaviru
came
bat
